We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval
NICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval
The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence and an agreement from Roche to lower the cost of the breast cancer treatment.